GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Ability of Four Toothpastes to Remove Plaque

Not Applicable

Completed

Conditions: Dental Plaque

Interventions: Other: 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
Other: 67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
Other: 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
Other: 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride

First Posted Date: 2017-09-18

Last Posted Date: 2018-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT03285984

Subject Insights to Understand Rheumatoid Arthritis (RA)

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Other: Numerical rating scale
Other: Real-time data capture app

First Posted Date: 2017-09-15

Last Posted Date: 2018-08-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT03285191

Locations: 🇬🇧
GSK Investigational Site, Bollington, Cheshire, United Kingdom

Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.

Completed

Conditions: Malaria

First Posted Date: 2017-09-13

Last Posted Date: 2025-01-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1500

Registration Number: NCT03281291

Locations: 🇰🇪
GSK Investigational Site, Kisumu, Kenya

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

Phase 2

Completed

Conditions: Respiratory Disorders

Interventions: Biological: Placebo
Biological: NTHi Mcat investigational vaccine (GSK3277511A)

First Posted Date: 2017-09-13

Last Posted Date: 2021-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 606

Registration Number: NCT03281876

Locations: 🇬🇧
GSK Investigational Site, Southampton, United Kingdom

Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England

Completed

Conditions: Influenza, Human

Interventions: Other: Enhanced vaccine safety surveillance

First Posted Date: 2017-09-11

Last Posted Date: 2020-01-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23939

Registration Number: NCT03278067

Locations: 🇬🇧
GSK Investigational Site, Surrey, United Kingdom

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: RTS,S/AS01E (Full dose)
Biological: Rabies vaccine
Biological: RTS,S/AS01E (1/5th dose)

First Posted Date: 2017-09-08

Last Posted Date: 2024-05-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1500

Registration Number: NCT03276962

Locations: 🇰🇪
GSK Investigational Site, Kisumu, Kenya

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: D-SUIV cH8/1N1+AS03
Biological: D-SUIV cH8/1N1+AS01
Biological: D-SUIV cH8/1N1
Biological: D-SUIV cH5/1N1+AS01
Biological: D-SUIV cH5/1N1+AS03
Biological: D-SUIV cH5/1N1
Biological: Fluarix Quadrivalent
Biological: D-SUIV cH11/1N1+AS03
Biological: Placebo
Biological: D-SUIV cH11/1N1+AS01
Biological: D-SUIV cH11/1N1